Organic Active Ingredients TRIZ Cases

Separating R-ketamine from S-ketamine targets inflammation and bone disease while addressing side effects that limit long-term treatment.

Limited camptothecin ADC options are addressed with fluoroalkyl payloads, defined DAR values, and targeted antibody delivery.

A split intra- and extragranular formulation packs raltegravir potassium into one tablet while preserving physical properties.

Formula (I) tetrahydronaphthalene compounds address limited survival in ER+, HER2- metastatic breast cancer through estrogen receptor degradation.

Repeated catheterization and slow drug response complicate AUR care; a single teverelix dose targets prostate enlargement to limit recurrence.

Oxycycloalkyl groups and modular linkers tune camptothecin ADC payloads for tumor targeting, antitumor activity, and toxicity profiles.

Specific 2′-halogen substitutions support efficient mRNA capping, in vitro transcription, cellular translation, and lower immunogenicity.

High-humidity exposure can increase related substances in FTD–TPI formulations; 85% critical-RH excipients help preserve stability.

A water-insoluble carrier lets saliva mobilize cannabinoids gradually, replacing rapid smoking absorption with adjustable oral dosing.

Specific amino acids promote caspase 14, desmoglein-1, and protein-glutamine γ-glutamyltransferase E production to improve moisture, barrier function, spots, and pH.

Acidified lower alcohol extraction, pH adjustment, and low-temperature crystallization produce cytisine at 98–99.9% purity and 80–85% yield.

A borate-polyol system with reduced benzalkonium chloride supports antimicrobial protection and ocular tolerability in multidose glaucoma treatment.

Oxidation-sensitive biopterin derivatives are stabilized in a solid phosphate-salt composition, then reconstituted for intravenous infusion.

Modified isoquinolinone derivatives use targeted substituents to improve membrane permeability and pharmacokinetics for glaucoma and ocular hypertension treatment.

RIAA selectively activates RIG-I to raise perforin and granzyme B in cytotoxic cells without unwanted interferon responses.

An ab-interno curved cannula reaches Schlemm’s canal through the anterior chamber, reducing external dissection and supporting aqueous humor drainage.

Phosphorothioate CpG oligonucleotides activate TLR9, raise interferon-gamma, and support durable tumor inhibition.

Immortalized corneal stromal stem cells produce defined exosome cargos for injection or contact-lens delivery to reduce and prevent scars.

A controlled oral release profile delivers 50% to 98% of daily minoxidil within 12 hours, limiting peak-related adverse effects.

A multi-ceramide topical composition boosts mitochondrial ATP production and respiratory-chain proteins to address oxidative damage and skin aging.

XRPD, DSC, and TGA distinguish crystalline and amorphous Bcl-2 inhibitor forms, supporting choices for solubility, stability, and bioavailability.

Target MYCT1 in endothelial cells to suppress tumor angiogenesis, enhance high endothelial venule formation, and create an immunostimulatory microenvironment.

Measure NRF2 splice variants and target genes to identify pathway-dependent cancers and guide antagonist treatment.

Hydroxyalkyl and heteroaryl substituents tune these compounds for NaV1.8 selectivity and potency while limiting off-target sodium channel effects.

To address cisplatin resistance in HGSOC, siRNA liposomes silence CASC10 and related targets to reduce tumor growth.

Conventional NASH therapies offer limited fibrosis and inflammation relief; CCK receptor inhibition targets the pathway to prevent HCC.

Topical corticosteroids and calcineurin inhibitors may provide incomplete relief; IL-4R antibody treatment lowers AD symptoms and biomarkers.

An ammonium sulfate inner phase and tuned lipid ratios help retain encapsulated drug, raise AUC, and limit insoluble particulates.

Combining an SGLT-2 inhibitor with an angiotensin II receptor blocker targets NAFLD fat accumulation in one treatment regimen.

Shortened and chemically modified hepcidin mimetics target ferroportin to reduce hematocrit in PV while easing synthesis.

Arginine solubilizes ibuprofen while the buffer-free injectable composition maintains near-physiological pH without sodium or dextrose.

Combining parathyroid hormone, osteoclast inhibitors, and a collagen-hydroxyapatite scaffold targets delayed healing while supporting bone formation.

An in situ HCl process in 1-propanol addresses costly, inefficient synthesis of diazaspiro pyridopyrimidinone pharmaceutical compounds.

MTAP loss elevates MTA in tumor cells; these tricyclic carboxamides target MTA-bound PRMT5 for greater selectivity over normal tissues.

HLA-matched peptides and TCR-bearing T cells target KK-LC-1 cancers, improving CTL induction and cytotoxic activity across HLA-C*14 and HLA-B*15.

GLP-2 derivatives target GVHD, including steroid-refractory cases, to improve survival and reduce disease symptoms.

This case shows how a 5′-O-acetoacetyl diacetyluridine prodrug improves oral uridine absorption while delivering acetoacetate for conversion to beta-hydroxybutyrate.

Plant-derived carotenoids may not increase butyrate production; microbial carotenoids shift gut composition and help restore intestinal barrier integrity.

Separate Telmisartan and SGLT-2 dosing can reduce convenience and compliance; a single tablet uses excipients to preserve stability and dissolution.

Protein hydrolysate-prebiotic conjugates resist digestive degradation while supporting sustained probiotic growth in the colon.

Limited antiviral efficacy and safety data motivate avermectin derivatives with tailored substituents for activity against SARS-CoV-2 and other coronaviruses.

Oral oxo-pyridine compounds target FXI to combine antithrombotic activity with rapid elimination and lower bleeding risk.

Forming a self-emulsifying delivery system before buffer addition stabilizes flavor emulsions and controls particle size in oral products.

A localized C4′ modification of the cannabidiol core creates a synthetic derivative with anticonvulsant activity in mouse models.

Targeted spermine-backbone modifications create SD1 to suppress type I interferon and interleukin-2 responses.

A localized Michael acceptor covalently binds KRAS G12C, inhibiting its pro-survival conformation with selective antiproliferative effects.

A medicated polymer sheath around a drug-loaded core supports independent, zero-order release of two active ingredients without dose dumping.

Low water solubility limits vitamin E glycosides in skin formulations; 1,2-hexanediol helps create a stable aqueous composition.

Acidic water with methanol or acetonitrile enables simple, accurate HPLC measurement of phenylhydrazine in pyrazolinone bulk drug.

Multiple crystal forms and X-ray diffraction profiles support stable KRAS G12D inhibitor development and storage.